N/A N=66 "Laparoscopic" Cystoscopy Versus Traditional Cystoscopy
Lower Urinary Tract Injury
Primary: Time Required to Perform Procedure (in Seconds) — 137; 451 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=350 Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial
Bladder Cancer Requiring Cystectomy
Primary: Percentage of Participants With 2-year Progression Free Survival (PFS) — 71.6; 72.3 percentage of participants
Phase 2 N=77 S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
Bladder Cancer · Transitional Cell Cancer of the Renal Pelvis and Ureter · Urethral Cancer
Primary: Pathologic Complete Response Rate by Transurethral Resection of Bladder Tumor (TURBT) and Imaging Studies After Chemotherapy — 46 percentage of participants
N/A N=73 Real-world Evidence Study on Cystistat
Interstitial Cystitis and Bladder Pain Syndrome
Primary: Patient Global Assessment (PGA) — 90.1 percentage of participants (%)
Phase 3 N=160 Thoracic Epidural Analgesia Versus Rectus Sheath Block Versus Surgeon Infiltration With Liposomal Bupivacaine or Standard Bupivacaine for Post-Operative Pain Control After Cystectomy
Cystectomy
Primary: VAS Score at 48 Hour — 5; 7; 4; 6 score on a scale
Phase 2 N=11 Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder
Bladder Cancer
Primary: Median Yield of Robot Assisted and Second Look Open Pelvic Lymph Node Dissection to Compare the Lymph Node Yield Achieved — 43; 4 Nodes (Node Yield)
Phase 2 N=18 Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy
Stage I Bladder Cancer AJCC v8 · Stage II Bladder Cancer AJCC v8 · Stage III Bladder Cancer AJCC v8
Primary: Toxicity for Safety Monitoring (TOX) — 15 percentage of participants
Phase 2 N=28 Bristol Bladder Trial
Infiltrating Bladder Urothelial Carcinoma
Primary: Overall Pathological Response Rate — 57.7 % of participants
Phase 3 N=133 Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
Bladder Cancer
Primary: Complete Response Rate at 3 Months — 39 percentage of participants
Phase 2 N=97 Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer
Bladder Cancer
Primary: Treatment Completion Rate — 67; 53 percentage of participants
N/A N=36 Rigid Versus Flexible Cystoscopy in Women
Hematuria · Urination Disorders · Voiding Dysfunction
Primary: Visual Analog Scale for Pain — 1.8; 1.4 Units on a Scale — p=.39
Phase 4 N=94 Oral Nutrition After Regular Radical Cystectomy
Post Cystostomy
Primary: the Postoperative Length of Stay — 18; 14 day — p=<0.001
Phase 4 N=242 Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection
Urinary Tract Infections
Primary: Urinary Tract Infection — 11; 12 UTI
Phase 2 N=43 BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
Muscle Invasive Bladder Cancer
Primary: Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging…
Phase 2 N=36 First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Primary: Median Overall Survival — 13.9 months
Phase 2 N=18 Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Bladder Cancer · Urinary Bladder
Primary: The Pathologic Complete Response Rate (<pT0) of Neoadjuvant GCS Regimen in Patients With Muscle-invasive Bladder Cancer. — 6.67 percentage of participants
N/A N=34 Steps to Eliminate Postoperative Problems
Bladder Cancer
Primary: Number of Days Step Goal Completed — 4.5; 9 days
N/A N=551 Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB
Bladder Cancer
Primary: Recurrence Free Survival — 9.6; 16.4 months — p=0.056
N/A N=25 Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder
Transitional Cell Carcinoma of the Bladder
Primary: Feasibility — 8; 15 participants
N/A N=25 Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder Cancer
Bladder Cancer · Low Testosterone Levels
Primary: Number of Hypogonadism in Participants Based on Serum Testosterone 90 Days Post Radical — 6 participants
N/A N=214 Cystoinflation to Prevent Bladder Injury in Obstetrics and Gynaecology Surgery
Bladder Injury · Complications; Cesarean Section · Adhesions Pelvic
Primary: Bladder Injury Rate — 3; 22 Participants — p=<.0001
Phase 3 N=25 Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy
Bladder Carcinoma
Primary: Patient Total Equivalent Analgesic Requirement (Morphine Equivalents) — 297.65; 396.16 Total oral morphine equivalents in mg
Phase 3 N=82 The Bladder Instillation Comparison Study
Urinary Bladder Neoplasms
Primary: Number of Participants Without Grade ≥ 3 Adverse Event, Graded According to NCI CTCAE Version 4.03 — 15; 14; 20 Participants
N/A N=174 Recovery Support for Bladder Cancer Patients and Caregivers
Bladder Cancer · Patient Engagement · Patient Empowerment
Primary: Quality of Life Patient: The Functional Assessment of Cancer Therapy-Bladder Cancer-Cystectomy — 117.59; 118.70 Quality of Life Score — p=0.772
N/A N=61 FITBIT Study on Mobility and Readmissions After Radical Cystectomy
Bladder Cancer
Primary: Change in Mean Daily Step Count From the Baseline Step Count During Two Days After the Surgery to the Hospital Discharge — 1087; 995 mean change in daily steps
N/A N=99 Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis
Anterior Vaginal Wall Prolapse · Cystocele · Pelvic Organ Prolapse
Primary: Prospective Randomized Trial of Anterior Colporrhaphy Vs. Cystocele Repair Using Polypropylene Mesh or Porcine Dermis — 5; 14; 12 Participants
N/A N=199 Patient Satisfaction Study: Clean Intermittent Self-Catheterization Teaching
Anxiety
Primary: State-Trait Anxiety Inventory-State Scores — 37.9; 40.7; NA; 37.7 units on a scale
N/A N=100 Trial Comparing Outpatient Flexible to Rigid Cystoscopy in Females
Pain
Primary: Post Procedural Complications, Including Frequency, Urgency, Infection and Time to Resolution of These Symptoms Between the Two Procedures. — 17; 15; 5; 15 participants
Phase 2 N=29 Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma
Urothelial Carcinoma
Primary: Bladder Tumor Recurrence Rate — 41.37 percentage of subjects
Early Phase 1 N=15 Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer
Transitional Cell Carcinoma of Bladder · Superficial Bladder Cancer
Primary: Safety and Tolerability — 5; 2; 1; 1 Grade 1/2 event count (no grade 3+)